A citation-based method for searching scientific literature

Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya, Lars Hansen, Fredrik Thorén, Anna Maria Langkilde. Diabetes Care 2018
Times Cited: 119



Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
Times Cited: 106




List of shared articles



Times cited


Current and future therapies for type 1 diabetes.
Bernt Johan von Scholten, Frederik F Kreiner, Stephen C L Gough, Matthias von Herrath. Diabetologia 2021
8


Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges.
Nuria Vilarrasa, Patricia San Jose, Miguel Ángel Rubio, Albert Lecube. Diabetes Metab Syndr Obes 2021
0

Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
Thomas F Dejgaard, Bernt J von Scholten, Erik Christiansen, Frederik F Kreiner, Lars Bardtrum, Matthias von Herrath, Chantal Mathieu, Sten Madsbad. Diabetes Obes Metab 2021
0

Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy.
Melissa-Rosina Pasqua, Michael A Tsoukas, Ahmad Haidar. J Diabetes Sci Technol 2021
0

Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice.
Ane Bayona Cebada, Lía Nattero-Chávez, Sara Alonso Díaz, Héctor F Escobar-Morreale, Manuel Luque-Ramírez. Diabetes Technol Ther 2020
1

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
Marc Evans, Debbie Hicks, Dipesh Patel, Vinod Patel, Phil McEwan, Umesh Dashora. Diabetes Ther 2020
15

Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Jennifer R Snaith, Deborah J Holmes-Walker, Jerry R Greenfield. Trends Endocrinol Metab 2020
8

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, Eiichi Araki, Marcus Lind, Niki Arya, Fredrik Thorén, Markus F Scheerer, Nayyar Iqbal, Paresh Dandona. Diabetes Obes Metab 2020
14

Non-insulin therapies in addition to insulin in Type 1 DM treatment.
Andrea Llano, Gerard A McKay. Br Med Bull 2020
1

Pharmacological therapies to address obesity in type 1 diabetes.
Anna Casu, Anika Bilal, Richard E Pratley. Curr Opin Endocrinol Diabetes Obes 2020
1

An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes.
Georgios Chatzopoulos, Konstantinos Tziomalos. Expert Opin Pharmacother 2020
1


Can exenatide flatten the post-prandial glucose curve in type 1 diabetes?
Charlotte K Boughton, Roman Hovorka. Ann Transl Med 2020
0

Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes.
Diana Isaacs, Stephanie Yager, Marcie Parker, Lauren Wolfe, Jennifer Luxenburg, Sanela Lekic. Ann Pharmacother 2019
3


Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
33

Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes.
Torben Biester, Olga Kordonouri, Thomas Danne. Diabetes Obes Metab 2019
5